News & Updates
Filter by Specialty:

Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
10 Jul 2024
IBS diagnosis tied to lower all-cause, cancer mortality
A diagnosis of irritable bowel syndrome (IBS), a common functional gastrointestinal disorder, appears to contribute to a reduced risk of death, but this association weakens over time, a study has shown.
IBS diagnosis tied to lower all-cause, cancer mortality
08 Jul 2024
Exercise, Mediterranean diet remain key against MASLD
A 12-week lifestyle intervention comprising a moderate-intensity physical activity (PA) programme and a hypocaloric Mediterranean diet (MD) promoted fat removal and liver fibrosis improvement in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), findings from the EHmet-DIA study suggest.